Manufacturing Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb PharmaTimesAragen scales Daretabart to commercial-ready production following rapid 9month tech transferRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) PharmaTimes Aragen scales Daretabart to commercial-ready production following rapid 9month tech transfer Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMsNext: BMS secures FDA acceptance for Camzyos sNDA Related Stories Manufacturing J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push pharminent July 15, 2026 Manufacturing Cellares and Sonoma partner to automate cell therapy manufacturing pharminent July 14, 2026 Manufacturing “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule pharminent July 13, 2026
